Headquartered in New York, NY·Fiscal year ends December·NASDAQ: DFTX·definiumtx.com
About Definium Therapeutics
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.
Its lead candidate, DT120 ODT, is a proprietary, pharmaceutically optimized orally disintegrating tablet of lysergide (LSD) tartrate. It acts as a partial agonist at 5-HT2A receptors and uses Catalent's Zydis fast-dissolve technology.
- **GAD:** positive results from three Phase 3 studies in GAD and MDD (Voyage, Panorama and Emerge), with an NDA filing targeted for the first half of 2027.
- **MDD:** the Phase 3 Ascend study is enrolling.
- **PTSD:** the Phase 3 Haven study is planned for 2027.
- DT120 holds FDA Breakthrough Therapy designation in both GAD and MDD.
The second program, DT402, is a proprietary R(-)-MDMA enantiomer being developed for core symptoms of autism spectrum disorder. It showed positive initial Phase 2a results.
The company is building commercial-readiness capabilities ahead of a potential launch. Any launch would depend on FDA approval and DEA/state rescheduling of Schedule I substances. Definium held approximately $1.05 billion in cash, cash equivalents and investments, which it expects to fund operations into 2030. Updated
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market…
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.
What is the DFTX stock price target?
The Wall Street consensus 12-month price target for DFTX is $72.83.